LONDON (ShareCast) - Shares in pharmaceuticals developer BTG fell even though it reported a sharp rise in revenues from £30.2m to £47.9m in the six months to
There is cash in the bank of £79.2m and net cash of £77.5m.
Analysts' reaction to the figures is far more positive than the fall in the share price suggests. KBC Peel Hunt says "BTG is fast becoming a sustainably profitable speciality pharma company". It also believes that BTG is in a strong position to grow in the US. The broker has set a target price of 240p a share.
KBC Peel Hunt believes that BTG can cut more of its costs and is on course for annual profits of around £20m from 2010-11.
FinnCap is also positive about BTG but it is disappointed by the lack of clarity on the Varisolve strategy. Varicose veins treatment Varisolve is progressing towards phase III trials in the US. BTG says that it is exploring commercial options for the drug.
Insurance outsourcing services provider Innovation Group was boosted by news that Legal & General has taken its stake from around 3% to 5.1%. Last month, Innovation won a £3.6m, three year contract with a UK friendly society.
Copyright © 2009